Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Japan Modified COCOON trial: preventive dermatologic intervention with amivantamab plus lazertinib in EGFR-mutated NSCLC
jRCTs041250135Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amivantamab, lazertinib, minocycline, doxycycline, hydrocortisone butyrate and 2 more in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of patients with grade ≥ 2 dermatologic adverse events of interest within 12 weeks. Started Dec 2025; status: active, not recruiting.
02
Drugs
amivantamablazertinibminocyclinedoxycyclinehydrocortisone butyrate
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs041250135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250135.